OS Therapies Incorporated
OSTX
$1.68
$0.021.21%
AMEX
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 33.56% | -36.61% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 42.18% | -3.22% | |||
| Operating Income | -42.18% | 3.22% | |||
| Income Before Tax | -51.64% | -17.02% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -51.64% | -17.02% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -51.64% | -17.02% | |||
| EBIT | -42.18% | 3.22% | |||
| EBITDA | -42.92% | 5.45% | |||
| EPS Basic | -19.21% | 0.99% | |||
| Normalized Basic EPS | -19.13% | 0.96% | |||
| EPS Diluted | -19.21% | 0.99% | |||
| Normalized Diluted EPS | -19.13% | 0.96% | |||
| Average Basic Shares Outstanding | 27.24% | 18.19% | |||
| Average Diluted Shares Outstanding | 27.24% | 18.19% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||